Strides Pharma receives USFDA approval for neuro drug

Strides Pharma Science, Bengaluru-based pharma company announced that its step-down wholly-owned subsidiary, Strides Pharma Global Pte. Limited, Singapore has received USFDA approval for Ethosuximide Softgel Capsules.

The said medicines are used to control sudden loss of consciousness and uncontrolled jerking movements in adults and children.

The company has 86 cumulative ANDA filings with USFDA out of which 57 have been approved including 13 approvals already received in FY19. During the recent quarter Q3FY19, the company has posted 6 per cent YoY growth in its topline.

On Wednesday, the stock of Strides Pharma Science opened at Rs. 406 per share and made an intraday high and low of Rs. 411.85 and Rs. 403.90 per share on the BSE. At 14:22, the stock was trading at Rs. 406.15 per share, up by 0.81 per cent on the BSE. The stock had hit its 52-week high of Rs. 757.81 on February 20, 2018 and its 52-week low of Rs. 334.10 on June 8, 2018 on the BSE.